Logo Logo
Switch Language to German

Kim, D.; Tiseo, M.; Ahn, M.; Reckamp, K.; Hansen, K. Holmskov; Kim, S.; Huber, R.; West, H.; Groen, H.; Hochmair, M.; Leighl, N.; Gettinger, S.; Langer, C.; Paz-Ares Rodriguez, L.; Smit, E.; Reichmann, W.; Kerstein, D.; Haluska, F. and Camidge, D. (2016): Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK plus Non-Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial. In: Annals of Oncology, Vol. 27: iv4-

Full text not available from 'Open Access LMU'.

Actions (login required)

View Item View Item